Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer’s disease by Panagiotis Alexopoulos et al.
RESEARCH Open Access
Conflicting cerebrospinal fluid biomarkers
and progression to dementia due to
Alzheimer’s disease
Panagiotis Alexopoulos1,2,9*†, Lukas Werle3†, Jennifer Roesler2, Nathalie Thierjung2, Lena Sophie Gleixner2,
Igor Yakushev4, Nikolaos Laskaris5, Stefan Wagenpfeil6, Philippos Gourzis1, Alexander Kurz2,
Robert Perneczky2,7,8 and for the Alzheimer’s Disease Neuroimaging Initiative (ADNI)
Abstract
Background: According to new diagnostic guidelines for Alzheimer’s disease (AD), biomarkers enable estimation of
the individual likelihood of underlying AD pathophysiology and the associated risk of progression to AD dementia
for patients with mild cognitive impairment (MCI). Nonetheless, how conflicting biomarker constellations affect
the progression risk is still elusive. The present study explored the impact of different cerebrospinal fluid (CSF)
biomarker constellations on the progression risk of MCI patients.
Methods: A multicentre cohort of 469 patients with MCI and available CSF biomarker results and clinical follow-up
data was considered. Biomarker values were categorized as positive for AD, negative or borderline. Progression risk
differences between patients with different constellations of total Tau (t-Tau), phosphorylated Tau at threonine 181
(p-Tau) and amyloid-beta 1–42 (Aβ42) were studied. Group comparison analyses and Cox regression models
were employed.
Results: Patients with all biomarkers positive for AD (N = 145) had the highest hazard for progression to dementia
due to AD, whilst patients with no positive biomarkers (N = 111) had the lowest. The risk of patients with only
abnormal p-Tau and/or t-Tau (N = 49) or with positive Aβ42 in combination with positive t-Tau or p-Tau (N = 119) is
significantly lower than that of patients with all biomarkers positive.
Conclusions: The risk of progression to dementia due to AD differs between patients with different CSF biomarker
constellations.
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Background
An increasing body of evidence suggests that Alzheimer’s
disease (AD) pathophysiology can be identified using bio-
markers [1, 2]. AD is characterized by abnormal patterns
in structural and functional imaging as well as by a
pathological cerebrospinal fluid (CSF) signature [3]. The
pathological CSF signature is defined by decreased CSF
concentrations of the peptide amyloid-beta 1–42 (Aβ42)
and increased levels of the proteins total Tau (t-Tau) and
Tau phosphorylated at threonine 181 (p-Tau). It is of note
that biomarkers reflect AD neuropathological changes
with relatively high accuracy [4, 5]. In clinical practice,
CSF biomarkers aid clinicians with decision-making, em-
body a key tool in the differential diagnosis especially of
atypical dementia syndromes and increase diagnostic con-
fidence [4, 6–9].
Biomarkers enable the identification of AD patho-
physiology in pre-dementia stages of the disease, such as
the stage of mild cognitive impairment (MCI) [10]. MCI
is a clinical entity characterized by cognitive deficits
which are so mild that activities of daily living remain
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largely unaffected [10]. It is a heterogeneous clinical syn-
drome with regard to aetiology, clinical appearance and
prognosis. MCI can be caused by different diseases (e.g.
AD, cerebrovascular disease, depression, frontotemporal
lobar degenerations, etc.). As a consequence, only some
patients with MCI progress to dementia due to AD or to
other dementias within limited time periods, while cog-
nitive functioning remains stable or even reverses to
normal in others [11–15]. Biomarkers embody a valuable
instrument in estimating the likelihood that MCI is
engendered by AD. Interestingly, biomarkers are an inte-
gral part of the recently proposed National Institute on
Aging–Alzheimer’s Association (NIA-AA) guidelines for
the diagnosis of MCI in clinical research settings [16].
These guidelines suggest categorizing MCI according to
the individual likelihood of underlying AD pathophysi-
ology and the associated risk of developing AD dementia
in the future; the highest likelihood category is charac-
terized by biomarker findings pointing to the presence
of AD pathophysiology, whereas the lowest likelihood
category is characterized by findings not typical for AD.
However, the criteria do not consider conflicting bio-
marker constellations, although they are very common
in MCI [17–19].
A large number of studies have investigated the prog-
nostic utility of established AD biomarkers (for instance
[10, 20–28]), but none of them has taken into account
the NIA-AA guidelines in combination with exclusive
consideration of all three established CSF biomarkers.
To shed light on this grey area, we conducted a retro-
spective study focused on differences in progression to




The study sample encompassed data from all phases of
the AD Neuroimaging Initiative (ADNI) (ADNI 1, Go and
2), a collaborative project of academic institutions and pri-
vate corporations across the USA and Canada which
began in October 2004. The study is coordinated by the
Alzheimer’s Disease Cooperative Study at the University
of California, San Diego. The ADNI data are disseminated
by the Laboratory for Neuroimaging at the University of
Southern California. Data used in this study were obtained
from the ADNI database (www.adni-info.org) on 27
August 2014. Patients with MCI, fulfilling international
diagnostic criteria [16], and with available CSF Aβ42,
t-Tau and p-Tau values at baseline and clinical follow-up
data were included. In the ADNI, patients with MCI had
Mini-Mental-State Examination (MMSE) scores between
24 and 30, a Clinical Dementia Rating (CDR) score of 0.5,
memory complaints and objective memory deficits on the
Wechsler Memory-Scale-Logical Memory II test. They
were not significantly impaired in their activities of daily
living. Patients with diagnoses other than MCI at baseline,
controls and patients with MCI but not all CSF biomarker
findings available at baseline were excluded from the
study. Patients diagnosed with AD dementia at follow-up
met the NIA-AA diagnostic guidelines for dementia due
to probable AD [1]. Regarding MCI patients who had not
progressed to dementia but discontinued participation in
follow-up visits or died, the data of their last follow-up
visit were considered in the analysis.
CSF collection and analysis
CSF collection, shipping, aliquoting, storage and analysis
took place according to ADNI standard operating proce-
dures (SOPs) [29]. It is noteworthy that some early CSF
samples were mistakenly collected into inappropriate
CSF collection tubes at the ADNI sites. However, this
was corrected rapidly and the exposure time to any in-
appropriate CSF collection tube was of limited signifi-
cance due to the short time the CSF was in contact with
the transfer tubes (approximately 25.7 min) [29]. ADNI
baseline CSF samples were analysed at the ADNI bio-
marker core laboratory at University of Pennsylvania ac-
cording to published methods [5, 30]. CSF samples were
put into the freezer at –80 °C. The CSF concentrations
of Aβ42, t-Tau and p-Tau were measured using the
multiplex xMAP Luminex platform with Innogenetics
immunoassay kit-based reagents (INNO-BIA AlzBio 3;
Ghent, Belgium) [30].
APOE genotyping
APOE genotypes were determined for all ADNI partici-
pants through analysis of blood samples using standard
polymerase chain reaction methods [31].
Classification of patients with MCI
In line with the NIA-AA algorithm, each patient’s bio-
marker values were categorized as either positive for
AD, negative for AD or borderline. The definition of the
range of borderline values was based on biomarker cut-
off values and standard deviations (SDs) selected from
previous reports on ADNI MCI patients [5]. The range
of borderline values was specified with the aim to reach
a reasonable compromise between minimizing the
chance of an artificial categorization as positive and at
the same time classifying less than 20% of the measured
values of each biomarker as borderline. Values within
20% of the SD from the respective cut-off point were
classified as borderline [32]. Aβ42 concentrations lower
than the defined range of Aβ42 borderline values and
t-Tau and p-Tau levels higher than the respective border-
line ranges were assumed to be AD positive. All other
biomarker values were considered negative. Aβ42, t-Tau
and p-Tau concentrations <181 pg/ml, >105.2 pg/ml,
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and >26.6 pg/ml, respectively, were thus regarded as posi-
tive for AD. CSF levels of Aβ42 > 203 pg/ml and t-Tau and
p-Tau concentrations <80.8 pg/ml and <19.4 pg/ml, re-
spectively, were considered negative for AD.
Patients were classified according to their fluid bio-
marker profile into the following subgroups:
 MCI with no positive biomarkers (MCINon+).
 MCI with all biomarkers positive (MCIAll+).
 MCI with positive Aβ42 but negative or borderline
p-Tau and t-Tau (MCIAβ+).
 MCI with positive Aβ42 and positive p-Tau or t-Tau
(MCIAβ+T+).
 MCI with negative or borderline Aβ42 but positive
p-Tau and/or t-Tau (MCIT+).
The biomarker constellations of the three latter sub-
groups are so far not being considered in the NIA-AA
diagnostic guidelines, because for MCI patients with
such biomarker constellations no likelihood grade for the
presence of AD pathology is assigned by the NIA-AA
criteria [16].
Statistical analysis
The statistical analyses were performed in SPSS v19.0
for Windows (IBM Corp., Somers, NY, USA). Normal
distribution of data was checked using the Kolmogorov–
Smirnov test. The raw biomarker data of study participants
were graphically presented by means of non-negative
matrix factorization (NNMF) [32, 33], a data-learning tech-
nique particularly suited for analysing positive valued data
so that the available information is condensed in a low-
dimensional (2D) space. The overall set of measurements:
Xi = {Aβ42, t-Tau, p-Tau}unlikelyi, i = 1, 2, …, N,
where N is the total number of participants, was approx-
imated as:
X[N×3] ≈W[N×2]B[2×3]
in order to minimize the reconstruction error induced
by the Frobenius norm: ||X-WB||2. In this way, the vec-
tor of measurements Xi associated with the ith partici-
pant took the form of:
Xi =wi1B1 +wi2B2,
where B1 and B2 were the unit length vectors for a parsi-
monious 2D representation and wi1 and wi2 were the
corresponding components. Differences between the
MCI subgroups regarding demographic and CSF data,
MMSE scores, follow-up duration, presence of the APOE
ε4 allele and progression rates to dementia due to AD
were tested by analysis of variance (ANOVA), Bonferroni
post-hoc analysis, Kruskal–Wallis test, Mann–Whitney
test and chi-square test as appropriate. Differences in
the hazard of progression between the MCI subgroups
were analysed using Cox regression models, adjusting
for patient characteristics that significantly differed between
the subgroups. Two-sided p < 0.05 was considered statisti-
cally significant.
Results
A total of 469 MCI patients out of 1729 ADNI partici-
pants with available baseline data fulfilled the inclusionary
criteria of the study. APOE ε4 and sex distribution, as well
as age and MMSE scores, significantly differed between
the subgroups (Table 1). In particular, the MMSE scores
of the MCINon+ subgroup were significantly higher com-
pared with the scores of the MCIAll+ (p < 0.001) and
MCIAβ+T+ (p < 0.01) subgroups. MMSE scores in the
MCIAll+ subgroup were significantly lower in comparison
with those of the MCIAβ+ (p = 0.02), MCIAβ+T+ (p = 0.03)
and MCIT+ (p < 0.01) subgroups. Across the five studied
MCI subgroups, approximately 45% of patients had con-
flicting CSF biomarker constellations. Figure 1, a graphical
presentation of participants’ Aβ42, t-Tau and p-Tau CSF
levels using NNMF, points to the high variability of the
CSF biomarker findings in patients with MCI. Data
were available from clinical follow-up visits conducted
every 6 months up to 8 years after baseline. In total,
159 patients with MCI progressed to dementia due to
AD. No patient progressed to any other form of de-
mentia. The difference between the MCI subgroups in
the proportions of patients who developed dementia
due to AD within the follow-up period attained statis-
tical significance (p < 0.001), whilst the duration of the
follow-up period did not differ.
Cox regression analyses unveiled a significant associ-
ation between group membership and risk of progression
to AD dementia (P < 0.001), whilst sex, age and the pres-
ence of the APOE ε4 allele did not exert such an influence.
As expected, lower MMSE scores were related to a higher
hazard of developing dementia. The differences in pro-
gression risk between patients in the MCINon+ subgroup
and those with positive Aβ42 values (MCIAβ+, MCIAβ+T+,
MCIAll+ subgroups) reached statistical significance. In
addition, the MCIAll+ subgroup was at significantly higher
risk for progression compared with both the MCIAβ+T+
and MCIT+ subgroups. No further significant differences
with regard to progression risk were detected between any
other of the compared MCI subgroups (Table 2, Fig. 2).
The risk pattern in relation to different biomarker constel-
lations in MCI is presented in Fig. 3.
Discussion
In line with a number of previous reports [17–19], but
in contrast to others [8, 9, 34, 35], approximately half of
the MCI cases in our study had conflicting CSF bio-
marker constellations. This discrepancy in the frequency
of patients with conflicting CSF biomarker results could
be possibly attributed to differences in study design. For
instance, not all studies considered all three CSF AD
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Table 1 Characteristics of the study sample
MCI subgroup p value
MCINon+ MCIAβ+ MCIAβ+T+ MCIAll+ MCIT+
N 111 45 119 145 49
Age (years) 71.29 (7.83) 74.78 (6.59) 74.25 (7.06) 72.68 (7.40) 71.57 (9.00) 0.010
Education (years) 16.54 (2.70) 16.29 (3.07) 16.13 (2.77) 15.97 (2.83) 15.92 (2.86) 0.468
MMSE 28.13 (1.70) 27.64 (1.79) 27.42 (1.88) 26.93 (1.87) 27.92 (1.78) <0.001
Sex (male:female) 67:44 34:11 78:41 73:72 29:20 0.020
APOE ε4 carriers (%) 21.62 42.22 62.18 77.93 26.53 <.001
CSF Aβ42 (pg/ml) 232.59 (30.25) 140.81 (26.14) 132.81 (23.70) 134.98 (20.96) 232.93 (30.24) <0.001
CSF Aβ42 negative/borderline/positive for AD 87/24/0 0/0/45 0/0/119 0/0/145 39/10/0 <0.001
CSF p-Tau (pg/ml) 18.63 (4.44) 20.36 (4.45) 43.66 (16.00) 58.41 (2.53) 41.77 (13.58) <0.001
CSF p-Tau negative/borderline/positive for AD 57/54/0 18/27/0 0/2/117 0/0/145 0/0/49 <0.001
CSF t-Tau (pg/ml) 50.66 (18.12) 55.53 (17.28) 78.37 (18.06) 158.09 (46.47) 74.86 (34.40) <0.001
CSF t-Tau negative/borderline/positive for AD 106/5/0 42/3/0 59/58/2 0/0/145 29/15/5 <0.001
Follow-up period (months) 32.22 (23.34) 32.53 (23.50) 30.81 (22.34) 29.96 (21.01) 32.02 (11.64) 0.350
Dementia due to AD vs no dementia at follow-up 14:97 14:31 43:76 80:65 8:41 <0.001
Data presented as mean (standard deviation) or frequencies
AD Alzheimer’s disease, MCI mild cognitive impairment, APOE apolipoprotein E, MMSE Mini-Mental State Examination, CSF cerebrospinal fluid, Aβ42 amyloid-beta
1–42, p-Tau tau phosphorylated at threonine 181, t-Tau total tau, MCINon+ MCI without positive CSF biomarkers, MCIAβ+ MCI with positive Aβ42 and negative or
borderline p-Tau and t-Tau, MCIAβ+T+ MCI with positive Aβ42 and positive t-Tau or p-Tau, MCIAll+ MCI with Aβ42 and both t-Tau and p-Tau positive, MCIT+ MCI with
negative or borderline Aβ42 and at least p-Tau or t-Tau positive
Fig. 1 Condensed representation, as a 2D scatter plot, of the CSF biomarker values of the study participants. The ensemble of trivariate
measurements of CSF Aβ42, p-Tau and t-Tau for all participants was analysed via NNMF and approximated by means of a bivariate data swarm
that conveniently represents the total variation in the original data. Labels indicate the different groups and lend semantics to the plot. MCINon+
MCI without positive CSF biomarkers, MCIAβ+ MCI with positive Aβ42 and negative or borderline p-Tau and t-Tau, MCIAβ+T+ MCI with positive Aβ42
and positive t-Tau or p-Tau, MCIAll+ MCI with Aβ42 and both t-Tau and p-Tau positive, MCIT+ MCI with negative or borderline Aβ42 and at least
p-Tau or t-Tau positive
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biomarkers. In addition, past studies implemented a
dichotomization strategy in interpreting biomarker
findings, whilst in the present study biomarker values
were categorized as positive, negative or borderline in
line with the NIA-AA guidelines. Moreover, it is possible
that academic, research centres recruit more patients with
complex constellations of biomarker findings, whilst more
patients with AD-typical CSF profiles and consequently
more advanced neuropathology are recruited in non-
academic, clinical settings. Interestingly, it has been shown
that patients of a non-academic memory clinic suffered
from more severe clinical symptoms in comparison with
the patients of an academic memory clinic [36].
Constellations with conflicting CSF biomarker findings
are not currently being considered by the NIA-AA
criteria for MCI [16], and our study provides initial
evidence on the role of conflicting CSF biomarker con-
stellations for dementia risk estimation. Our findings
indicate that compared with the constellation without
positive biomarkers, the presence of Aβ42 positivity con-
fers a higher risk for future AD dementia irrespective of
t-Tau and p-Tau levels. Thus, it seems that Aβ42 is not
only the first marker to become positive in the course of
AD [37], but also the decisive marker to determine
dementia risk. Despite the absence of general consensus,
because a number of past reports point to a higher or
almost similar prognostic utility of tau peptides com-
pared with Aβ42 [20, 35, 38–42], our observations are in
line with several previous studies which showed that
Aβ42 has a higher prognostic utility in comparison with
tau or failed to find an association between tau and cog-
nitive deterioration [5, 22, 43, 44]. It is important to
mention, however, that our results cannot necessarily be
generalized to all patients with MCI, because the ADNI
MCI cohort is deliberately limited to those with promin-
ent memory deficits in order to enrich the sample with
pre-dementia AD cases. MCI is heterogeneous by defin-
ition, and the studied biomarkers may react differently in
early non-AD cases. Hence, the confounding effects of
other brain pathologies associated with increased p-Tau
and/or t-Tau levels (such as cerebrovascular changes,
Lewy bodies, etc.) are minimized in ADNI, so that the role
of Aβ42 as an indicator of AD pathophysiology may be
exaggerated. Furthermore, it should be underscored that
our findings could have been biased by the artificial defin-
ition of the range of borderline biomarker values as well
as by the fact that, due to sample size reasons, borderline
values were not considered separately from negative
values in our analyses. Interestingly, an alternative analysis
considering borderline and positive values together re-
sulted in an amelioration of the significance of the role of
Aβ42 (the results of the alternative analysis are presented
in Additional file 1). Hence, further studies with larger
samples enabling the separate consideration of borderline
values are warranted before definite conclusions can be
drawn.
The higher dementia risk in the MCIAll+ subgroup
compared with the other subgroups is in line with the
proposed model of a temporal evolution of AD bio-
markers as well as with a recently published, probabilis-
tic, data-driven model of biomarker changes in sporadic
AD, independent of a-priori patient staging and bio-
marker cut-off points [37, 45]. Our observation supports









0 =MCINon+* 0.992 0.009 2.697 1.279–5.686
1 =MCIAβ+
0 =MCINon+* 1.060 0.001 2.887 1.538–5.422
1 =MCIAβ+T+
0 =MCINon+* 1.481 <0.001 4.399 2.417–8.006
1 =MCIAll+
0 = MCINon+* 0.591 0.185 1.806 0.753–4.330
1 =MCIT+
0 = MCIAβ+* 0.068 0.828 1.071 0.578–1.983
1 =MCIAβ+T+
0 =MCIAβ+* 0.489 0.105 1.631 0.903–2.945
1 =MCIAll+
0 = MCIAβ+* –0.401 0.369 0.670 0.279–1.606
1 =MCIT+
0 = MCIAβ+T+* 0.421 0.029 1.524 1.045–2.222
1 =MCIAll+
0 = MCIAβ+T+* –0.469 0.234 0.625 0.289–1.355
1 =MCIT+
0 = MCIAll+* –0.890 0.02 0.410 0.194–0.870
1 =MCIT+
Age 0.007 0.536 1.007 0.985–1.030
Sex 0.021 0.905 1.021 0.727 – 1.434
0 = female*
1 =male
MMSE –0.215 <0.001 0.807 0.738 – 0.882
APOE ε4 –0.331 0.072 0.718 0.501 – 1.030




MCI mild cognitive impairment, MCINon+ MCI without positive cerebrospinal
fluid (CSF) biomarkers, MCIAβ+ MCI with positive amyloid-beta 1-42 (Aβ42) and
negative or borderline tau phosphorylated at threonine 181 (p-Tau) and total
tau (t-Tau), MCIAβ+T+ MCI with positive Aβ42 and positive t-Tau or p-Tau,
MCIAll+ MCI with Aβ42 and both t-Tau and p-Tau positive, MCIT+ MCI with negative
or borderline Aβ42 and at least p-Tau or t-Tau positive, MMSE Mini-Mental State
Examination; APOE apolipoprotein E
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the assumption that as clinical symptoms advance and
the threshold to dementia is reached, the abnormality of
biomarkers becomes evident [46, 47]. The lack of signifi-
cant difference in terms of dementia risk between the
MCIAll+ and MCIAβ+ subgroups is probably a spurious
finding, related to the relatively small size of the MCIAβ+
subgroup and/or the definition of the cut-off values.
This assumption is supported by the highly significant
difference between the MCIAll+ and MCIAβ+T+ sub-
groups, although the latter subgroup has a higher de-
mentia risk compared with the MCIAβ+ subgroup as
illustrated in Fig. 2. Moreover, the alternative analysis, in
Fig. 2 Cox regression survival curves for patients with MCI and different constellations of CSF Aβ42 and neuronal injury markers (p-Tau and t-Tau).
MCINon+ MCI without positive CSF biomarkers, MCIAβ+ MCI with positive Aβ42 and negative or borderline p-Tau and t-Tau, MCIAβ+T+ MCI with
positive Aβ42 and positive t-Tau or p-Tau, MCIAll+ MCI with Aβ42 and both t-Tau and p-Tau positive, MCIT+ MCI with negative or borderline Aβ42
and at least p-Tau or t-Tau positive
Fig. 3 Risk for progression to dementia due to AD of patients with MCI and different constellations of CSF Aβ42 and neuronal injury markers
(p-Tau and t-Tau). AD Alzheimer’s disease, MCINon+ MCI without positive CSF biomarkers, MCIAβ+ MCI with positive Aβ42 and negative or borderline
p-Tau and t-Tau, MCIAβ+T+ MCI with positive Aβ42 and positive t-Tau or p-Tau, MCIAll+ MCI with Aβ42 and both t-Tau and p-Tau positive, MCIT+ MCI
with negative or borderline Aβ42 and at least p-Tau or t-Tau positive
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which borderline and positive biomarker values were
treated as one group, unveiled a significant difference in
progression risk between the MCI subgroup with all
markers non-negative (positive or borderline) and the sub-
group with only Aβ42 non-negative (Additional file 1).
Thus, the observed lack of significant difference in demen-
tia risk between the MCIAll+ and MCIAβ+ subgroups should
be treated with caution. In addition, it is noteworthy that
our results confirm the approach of the NIA-AA algorithm
to assign the highest likelihood of AD to MCI patients with
all biomarkers positive.
Our findings suggest that MCI patients with positive
Aβ42 values are at the same risk for AD dementia
whether or not they have one positive Tau marker
(either t-Tau or p-Tau). Hence, patients with positive Aβ42
and non-positive or conflicting p-Tau/t-Tau levels, who
cannot be categorized according to the current NIA-AA
algorithm, seem to have the same dementia risk, which
lies between that of the lowest and highest risk groups
(MCINon+ and MCIAll+ respectively). However, this obser-
vation is in contrast with the findings of a large number of
previous reports which have shown that MCI patients
with two positive CSF markers have a higher risk to pro-
gress to dementia compared with MCI patients with only
one positive biomarker [20, 22, 25, 28, 40, 44, 48–51]. As
a result, this finding should be treated with caution. It can-
not be precluded that the observation of the present study
has been biased by the definition of the cut-off points
and/or by the relatively small size of the MCIAβ+ sub-
group. Nonetheless, the alternative analysis in which bor-
derline and positive biomarker values were treated as one
group (non-negative values) did not reveal significant dif-
ferences in the progression risk between the MCI sub-
group with only Aβ42 non-negative and that with both
Aβ42 and p-Tau or t-Tau non-negative (Additional file 1).
Further studies are thus required in order to shed more
light on the progression risk of the MCIAβ+ and MCIAβ+T+
subgroups.
In terms of dementia risk, MCI patients with one or two
positive Tau markers but negative or borderline Aβ42
values (MCIT+ subgroup) may be placed between patients
without positive biomarkers (MCINon+ subgroup) and
those with positive Aβ42 and non-positive or conflicting
p-Tau/t-Tau levels (MCIAβ+ and MCIAβ+T+ subgroup, re-
spectively). The term “suspected non-AD pathophysiology
(SNAP)” has recently been proposed to designate individ-
uals with abnormal markers of neuronal injury without evi-
dence of amyloid accumulation [10, 18, 52]. According to
our findings, the progression risk of the MCIT+ subgroup
does not significantly differ from that of the MCINon+ sub-
group. Simultaneously, it is no different from that of the
MCIAβ+ and MCIAβ+T+ subgroups. However, the dementia
risk of the two latter subgroups does in fact differ from
the MCINon+ subgroup. As a consequence, the MCIT+
risk can be placed between that of MCINon+ and MCIAβ+,
MCIAβ+T+ subgroups (Fig. 3). Nonetheless, this finding
should also be treated with caution due to the limited size
of the ADNI MCIT+ subgroup and because a prior study
showed that the highest proportion of subjects who pro-
gressed to dementia was observed not only in the MCI
subgroup with both amyloid and neuronal injury markers
positive for AD but also in the MCI subgroup with only
neuronal injury biomarkers positive [10]. This discrepancy
could be explained by the different markers of neuronal
injury considered in the two studies (neurochemical vs
imaging), especially in light of the pathophysiological char-
acter of the former and the downstream topographical
character of the latter [53].
The present study should be viewed in the light of some
limitations. Owing to the lack of histopathological verifica-
tion, the main outcome measure was based purely on clin-
ical diagnoses, which are not always confirmed at autopsy
[54]. Moreover, the ADNI encompasses individuals re-
cruited at specialized research centres and does not mirror
constellations in the community. This is clearly illustrated
by the fact that within the follow-up period only conversion
to dementia due to AD and not to other forms of dementia
was observed. Furthermore, in building the MCI subgroups
with distinct biomarker constellations we did not consider
borderline values separately from negative values, because
such an approach would have expanded the number of
MCI subgroups and reduce their size. This limitation could
explain the relatively high proportion—in comparison with
previous reports—of patients in the MCINon+ subgroup as
well as in the MCIT+ subgroup who progressed to dementia
due to AD [55], because it is possible that borderline bio-
marker values became positive shortly after baseline. In
addition, it can be reckoned that our observations are
biased by the artificial definition of the range of borderline
biomarker values. In light of the lack of empirical data with
regard to definitions of the range of borderline values, our
findings should be treated with caution. Nonetheless, the
NIA-AA guidelines clearly specify the presence of border-
line biomarker values. As a consequence, further studies
considering borderline biomarker values are warranted. A
further shortcoming of the study is the collection of some
early CSF samples into inappropriate tubes at the ADNI
sites. Although the error was corrected rapidly and despite
the relatively limited exposure time to any inappropriate
CSF collection tube, this error could embody a source of
bias because the use of different collection tubes increases
intra-laboratory variability [34, 56–58]. Moreover, we did
not take into account imaging biomarker data. However, it
should be underscored that while combining imaging with
neurochemical biomarker data may be relevant for re-
search settings, it is rarely applicable to clinical settings
because of limitations related to scanner equipment and
sophisticated image analyses expertise.
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Conclusions
The present study provides a further piece of evidence
for the prognostic differences between MCI subgroups
with distinct neurochemical biomarker constellations.
The study reveals significant differences between sub-
groups with conflicting biomarkers, on the one hand,
and patients with all neurochemical biomarkers positive
or non-positive (borderline or negative) for AD on the
other. Even though our observations exclusively refer to
neurochemical biomarkers and do not consider imaging
markers, they point to the necessity of modifying/refin-
ing the NIA-AA algorithms for categorizing MCI.
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